Alvin Kh Kwok

Epiretinal membrane surgery with or without internal limiting membrane peeling

Background:  The purpose of the present paper was to evaluate the visual outcome and recurrence rate of epiretinal membrane (ERM) formation following vitreoretinal surgery with and without internal limiting membrane (ILM) peel.

Macular hole surgery with or without indocyanine green stained internal limiting membrane peeling

Background: To compare the anatomical and visual outcome in primary idiopathic macular hole surgery with or without indocyanine green (ICG) stained internal limiting membrane (ILM) peeling.

Pars plana vitrectomy in the management of retained intravitreal lens fragments after cataract surgery

Purpose: To assess the outcome of patients who underwent pars plana vitrectomy for retained lens fragments after cataract surgery.

Anti‐vascular endothelial growth factor for myopic choroidal neovascularization

Myopic choroidal neovascularization (CNV) is a vision‐threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle‐aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized‐controlled study in treatment of subfoveal myopic CNV. However, its long‐term benefit is controversial. Recently, intravitreal injections of anti‐vascular endothelial growth factors have shown promising results. In the absence of randomized‐controlled trial comparing the efficacy of anti‐vascular endothelial growth factors with photodynamic therapy and placebo, the purpose of this article is to review the current studies on functional and anatomical outcomes in both subfoveal and juxtafoveal myopic CNV. Furthermore, the influences of various doses and frequencies, as well as age and previous photodynamic therapy treatment on its effect are described.Myopic choroidal neovascularization (CNV) is a vision-threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle-aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized-controlled study in treatment of subfoveal myopic CNV. However, its long-term benefit is controversial. Recently, intravitreal injections of anti-vascular endothelial growth factors have shown promising results. In the absence of randomized-controlled trial comparing the efficacy of anti-vascular endothelial growth factors with photodynamic therapy and placebo, the purpose of this article is to review the current studies on functional and anatomical outcomes in both subfoveal and juxtafoveal myopic CNV. Furthermore, the influences of various doses and frequencies, as well as age and previous photodynamic therapy treatment on its effect are described.

Simultaneous Central Retinal Vein Occlusion and Branch Retinal Artery Occlusion in a Young Patient with Gout

Purpose: To report a patient with combined, unilateral BRAO and CRVO that appeared after taking oral etoricoxib and diclofenac for 2 weeks for the first gouty attack. Methods: Observational case report Patient: A 34-year-old Chinese man Results: The BRAO resolved angiographically one day after high dose oral steroids were given. The best corrected visual acuity in the right eye was 20/20 with complete resolution of retinal hemorrhages two months later Conclusion: Simultaneous central retinal vein occlusion and branch retinal artery occlusion may be associated with oral non-steroidal anti-inflammatory drugs and gout.

Anti-vascular endothelial growth factor for myopic choroidal neovascularization: Anti-VEGF for myopic CNV

Myopic choroidal neovascularization (CNV) is a vision‐threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle‐aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized‐controlled study in treatment of subfoveal myopic CNV. However, its long‐term benefit is controversial. Recently, intravitreal injections of anti‐vascular endothelial growth factors have shown promising results. In the absence of randomized‐controlled trial comparing the efficacy of anti‐vascular endothelial growth factors with photodynamic therapy and placebo, the purpose of this article is to review the current studies on functional and anatomical outcomes in both subfoveal and juxtafoveal myopic CNV. Furthermore, the influences of various doses and frequencies, as well as age and previous photodynamic therapy treatment on its effect are described.Myopic choroidal neovascularization (CNV) is a vision-threatening complication in the eyes with pathological myopia, which is particularly prevalent among young and middle-aged Asians globally. To date, the verteporfin in photodynamic therapy study is the only randomized-controlled study in treatment of subfoveal myopic CNV. However, its long-term benefit is controversial. Recently, intravitreal injections of anti-vascular endothelial growth factors have shown promising results. In the absence of randomized-controlled trial comparing the efficacy of anti-vascular endothelial growth factors with photodynamic therapy and placebo, the purpose of this article is to review the current studies on functional and anatomical outcomes in both subfoveal and juxtafoveal myopic CNV. Furthermore, the influences of various doses and frequencies, as well as age and previous photodynamic therapy treatment on its effect are described.